Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | PRCP | P42785 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158806 | 1.00 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL31158866 | 1.00 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL12741563 | 1.00 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL13181686 | 0.85 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL19853263 | 0.85 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL23280449 | 0.82 | PNMT (0.59) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL20759206 | 0.81 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL10327325 | 0.81 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL10326622 | 0.81 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL21505499 | 0.81 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | PNMT 322/4885ADRA2A 33/4885ADRA2B 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.